NEW

Switch to Dark

Pricing

Learn

MRNA - Moderna Inc

161

$53.57

$0.03 (0.056%)

At market close

$53.41

-$0.16 (-0.307%)

After Hours 3/26/26, 8:33 PM

2.00/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

MRNA

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$21.16B

Industry

Biotechnology

EPS (TTM)

-$7.19

P/E (TTM)

0.00

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

10.89

P/B

2.45

Diluted Shares

392.00M

Ex-Dividend

--

Next Earnings

04-29

Forward P/E

0.00

Payout Ratio

--

P/FCF (TTM)

0.00

FCF Yield

--

Earnings Yield

-13.33%

52 Week Range

Score Card

Explore Scores Tab

2.00

Bad

Moderna Inc has a current cash runway of 33.54 months. The cash runway is the amount of time the business has at its current burn rate before it will need to take on debt or dilute shareholders to raise more money. Also, it has seen its revenue decline by -39.93% over the past year, which means the company is losing sales/customers.

Valuation Model

Key Score

4.00

Good

Management

5.00

Very Good

Growth

4.00

Good

Profitability

5.00

Very Good

Fin. Health

4.00

Good

Dividends

--

--

Analyst

3.00

Average

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

Filter Form Types

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-16 16:32:27

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-16 16:31:50

Form ARS

Unknown Form Type

Filed on 2026-03-16 16:31:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 16:24:57

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 16:21:25

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-04 20:20:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:19:47

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:14:55

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:10:53

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:04:51

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-02 09:56:47

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-25 16:49:00

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$141.75

164.6%

Avg:

$42.49

-20.7%

Low:

$12.12

-77.4%

(% change is relative to the current stock price: $53.57)

Analyst Recommendations

Go to Analyst Tab

2.80

Average

0%

Strong Buy (0)

10%

Buy (3)

70%

Hold (21)

10%

Sell (3)

10%

Strong Sell (3)

About

Website
https://www.modernatx.com/
Address
325 Binney Street, Cambridge MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1682852

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

IPO Date

2018-12-07

Industry

Biotechnology

Total Employees

4,700

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences